# Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

> **NCT06683131** · PHASE4 · NOT_YET_RECRUITING · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 1160 (estimated)

## Conditions studied

- Acute Myocardial Infarction (AMI)

## Interventions

- **DRUG:** Tafolecimab

## Key facts

- **NCT ID:** NCT06683131
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 1160 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06683131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06683131, "Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06683131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*